NewAmsterdam Pharma Company N.V. (NAMS) vs uniQure N.V. (QURE)
NewAmsterdam Pharma Company N.V. and uniQure N.V. are both Biotechnology companies. NewAmsterdam Pharma Company N.V. and uniQure N.V. are of similar size ($2.7B and $2.7B). uniQure N.V. grew revenue faster over the last twelve months: 30.2% against −88.9%. uniQure N.V. has the higher net margin (−1,350.7% vs −3,644.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, NewAmsterdam Pharma Company N.V. leads on 8 and uniQure N.V. on 8.
Valuation
Profitability
| Metric | NAMS | QURE | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 92.49% | 65.16% |
| Operating margin | (3,432.20%) | (1,071.53%) | 0.00% |
| Net margin | (3,644.21%) | (1,350.73%) | 0.00% |
| Free cash flow margin | (2,018.28%) | (864.67%) | 0.00% |
| Return on equity | (36.81%) | (157.61%) | (57.72%) |
| Return on assets | (34.16%) | (32.13%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack